ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces publication of the ...
Regulatory submission is based on positive results from the Phase 2 PROSPECT Study —– FDA sets PDUFA Date of December 18, 2026 —OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera ...
Researchers at City St. George’s, University of London, have identified a new molecular signature that may explain why patients with aggressive HER2-positive breast cancer developed resistance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results